Chethan Ramamurthy
Merck & Co., Inc., Rahway, NJ, USA (United States)
ORCID: 0000-0003-3935-9638Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer”.
Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar +20 more
Nabil Adra, Pongwut Danchaivijitr, Maksym Sabadash, Alejo Rodriguez-Vida, Zhentao Zhang +21 more
J. Robert Beck, Andres Correa, Chethan Ramamurthy, Daniel M. Geynisman, Elizabeth A. Handorf
Yidong Chen, Jonathan Gelfond, Teresa L. Johnson‐Pais, Robin J. Leach, Chethan Ramamurthy +3 more
Karen Wheeler, Shaun Trecarten, Zaineb Hassouneh, Niannian Ji, Yi‐Fen Lee +3 more